[
    [
        {
            "time": "",
            "original_text": "去年业绩大涨，检测巨头今年将面临“不合理医疗检查”大考",
            "features": {
                "keywords": [
                    "业绩",
                    "检测",
                    "不合理医疗检查"
                ],
                "sentiment_score": 0.2,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "检测"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "去年业绩大涨，检测巨头今年将面临“不合理医疗检查”大考",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "华大基因：减持计划时间已过半 和玉高林和高林同创未减持",
            "features": {
                "keywords": [
                    "华大基因",
                    "减持",
                    "股东"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物技术",
                    "基因检测"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "华大基因：减持计划时间已过半 和玉高林和高林同创未减持",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "华大基因：股东和玉高林和高林同创减持计划时间已过半，未减持股份",
            "features": {
                "keywords": [
                    "华大基因",
                    "股东",
                    "减持",
                    "股份"
                ],
                "sentiment_score": -0.1,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物技术",
                    "基因检测"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "华大基因：股东和玉高林和高林同创减持计划时间已过半，未减持股份",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "华大基因2020年净增长656% 2021年一季度增长275%",
            "features": {
                "keywords": [
                    "华大基因",
                    "净增长",
                    "2020年",
                    "2021年一季度"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物技术",
                    "基因检测"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华大基因2020年净增长656% 2021年一季度增长275%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "华大基因2020年净利润同比增长656%，拟每10股派3.5元",
            "features": {
                "keywords": [
                    "华大基因",
                    "净利润",
                    "同比增长",
                    "分红"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物技术",
                    "基因检测"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华大基因2020年净利润同比增长656%，拟每10股派3.5元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "华大基因去年净利润同比增加超6倍：新冠检测需求大幅增长",
            "features": {
                "keywords": [
                    "华大基因",
                    "净利润",
                    "新冠检测",
                    "需求增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物技术",
                    "基因检测",
                    "新冠检测"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华大基因去年净利润同比增加超6倍：新冠检测需求大幅增长",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "华大基因公布2020年报，营收为83.97亿元！",
            "features": {
                "keywords": [
                    "华大基因",
                    "年报",
                    "营收"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物技术",
                    "基因检测"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华大基因公布2020年报，营收为83.97亿元！",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "华大基因一季净利增长270%以上 多股业绩超预期",
            "features": {
                "keywords": [
                    "华大基因",
                    "净利增长",
                    "一季度",
                    "业绩超预期"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物技术",
                    "基因检测"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华大基因一季净利增长270%以上 多股业绩超预期",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]